Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mongersen in Active Ulcerative Colitis
NCT02601300Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2015
- Primary completion
- Sep 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of mongersen in ulcerative colitis (UC), sponsored by Celgene Corporation. Primary endpoint: Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Score (MMS) at 8 weeks. Started Dec 2015; status: completed.
02
Drugs
mongersen
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02601300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601300.